Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
Mirum Pharmaceuticals
ISIN US6047491013
|WKN A2PM29
Market cap (in EUR)
4,702 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
Overview
Description
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals United States
Financials
Key metrics
| Market capitalisation, EUR | 4,702 m |
| EPS, EUR | -0.42 |
| P/B ratio | 14.8 |
| P/E ratio | - |
| Dividend yield | 0.00% |
Income statement (2025)
| Revenue, EUR | 462 m |
| Net income, EUR | -21 m |
| Profit margin | -4.48% |
What ETF is Mirum Pharmaceuticals in?
There are 2 ETFs which contain Mirum Pharmaceuticals. All of these ETFs are listed in the table below. The ETF with the largest weighting of Mirum Pharmaceuticals is the iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).
| ETF | Weight | Investment focus | Fund size (in m EUR) |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 0.40% | Equity United States Health Care Biotech | 47 |
| JPMorgan BetaBuilders US Small Cap Equity UCITS ETF USD (dist) | 0.06% | Equity United States Small Cap | 187 |
Latest articles
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.